Medpage Today on MSN19h
Adding HIPEC Boosts Survival in Recurrent Ovarian CancerThe 5-year OS rates were 46% in the HIPEC group versus 38% in the no-HIPEC group, they noted in Lancet Oncology. The trial ...
Researchers found significant differences in ovarian cancer survival among Asian American subgroups, emphasizing the ...
Researchers from the Walter and Eliza Hall Institute (WEHI)in Australia have found a new way to predict a subset of patients ...
Nuvectis Pharma shares fell steeply after updated data from its early-stage study evaluating NXP800 to treat an aggressive type of ovarian cancer showed that a change in the dosing schedule only ...
University of Iowa researchers have landed a $10-million federal grant to develop a new treatment for ovarian cancer. Jill ...
A University of Iowa researcher is using federal funding to develop a new approach to combat ovarian cancer. According to the ...
A simple blood test could soon predict which ovarian cancer patients will stop responding to their treatment, paving the way ...
Data presented as part of a poster at the SITC 2024 ConferenceSOUTH SAN FRANCISCO, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics ...
Researchers at the University of California San Diego are hoping to drastically shorten the time between a cancer diagnosis ...
The Ovarian Cancer Research Alliance offers specialized services and support to help ovarian cancer patients find a community ...
CERo Therapeutics (CERO) announces the presentation of preclinical data demonstrating the capability of its lead compound CER-1236 to kill ...
The company has discontinued the Phase I/II trial of its only clinical candidate due to a potential “unfavourable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback